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Available online 16 July 2016Anti-VEGF antibody bevacizumab has prolonged progression-free survival in several cancer types, however ac-
quired resistance is common. Adaption has been observed pre-clinically, but no human study has shown timing
and genes involved, enabling formulation of new clinical paradigms.
In a window-of-opportunity study in 35 ductal breast cancer patients for 2 weeks prior to neoadjuvant chemo-
therapy, we monitored bevacizumab response by Dynamic Contrast-Enhanced Magnetic Resonance [DCE-
MRI], transcriptomic and pathology.
Initial treatment response showed signiﬁcant overall decrease in DCE-MRImedian Ktrans, angiogenic factors such
ESM1 and FLT1, and proliferation. However, it also revealed great heterogeneity, spanning from downregulation
of blood vessel density and central necrosis to continued growth with new vasculature. Crucially, signiﬁcantly
upregulated pathways leading to resistance included glycolysis and pH adaptation, PI3K-Akt and immune check-
point signaling, for which inhibitors exist, making a strong case to investigate such combinations.
These ﬁndings support that anti-angiogenesis trials should incorporate initial enrichment of patients with high
Ktrans, and a range of targeted therapeutic options to meet potential early resistance pathways. Multi-arm adap-
tive trials are ongoing using molecular markers for targeted agents, but our results suggest this needs to be fur-
ther modiﬁed by much earlier adaptation when using drugs affecting the tumor microenvironment.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Radiogenomics1. Introduction
Angiogenesis is a key process in cancer providing oxygen and nutri-
ents to the growing tumor mass. Key player is the vascular endothelial
growth factor [VEGF], targeted by antibodies or small molecule kinase
inhibitors. First such agent was bevacizumab [Avastin], monoclonal an-
tibody against VEGF. Clear activity in clinical trials has led to implemen-
tation of such therapies as standard of care. However, effects are usually
on progression–free rather than overall survival, and often measured in
weeks (Carmeliet and Jain, 2000). Whilst beneﬁt has been shown in
some cancers, in breast cancer there has been controversy on the role
of antiangiogenic therapy (Rossari et al., 2012). Early studies showedF.M. Buffa),
. This is an open access article underimprovement of response in metastatic disease with Taxol (Jain,
2014), whilst neoadjuvant studies showed contrasting results (Jain,
2014; Bear et al., 2012; Earl et al., 2015; Sikov et al., 2015; von
Minckwitz et al., 2012).
Lack of consensus between clinical trials has questioned the effec-
tiveness of bevacizumab in breast cancer, and the drug is no longer in
use in several countries. However, there is large evidence of heterogene-
ity of response. Therefore we undertook a study in the situation where
bevacizumabwas approved to understandmechanisms behind this het-
erogeneity, and clinical implications. Circulating levels of short VEGFA
isoforms, neuropilin-1 and VEGF receptor 1 expression in tumours or
plasma, and VEGFA genetic variants have been reported as potential
biomarkers of bevacizumab response (Lambrechts et al., 2013; Hegde
et al., 2013). Changes in DCE-MRI parameters with therapy have been
shown, such as volume transfer constant (Ktrans), complex function of
vessel permeability, surface area and tumor blood ﬂow; however, how
to use MRI to impact on drug therapy modulation is controversial
(O'Connor and Jayson, 2012); reﬂecting limited insight into molecularthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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monitoring with limited number of molecular markers, showed reduc-
tion of perfusion parameters with increase in tumor apoptosis
(Wedam et al., 2006). However, studies to date have been hindered
by either combination with chemotherapy, or focus on advance cancers
where multiple resistance mechanisms are likely to have developed, or
else limited pharmacodynamics assessments probing only someaspects
of tumor response.
The present single-agent bevacizumab study, in previously untreat-
ed primary breast cancer patients, asks whether DCE-MRI
complemented with molecular proﬁling of response could provide
criteria for patient stratiﬁcation and insight into early actionable path-
ways of resistance.
2. Methods
2.1. Study Design and Participants
A phase II, non-randomized, open-label study sponsored by Oxford
Radcliffe Hospitals NHS Trust (ORH/PID/5575) was given National Re-
search Ethics Services, UK, approval (Oxford REC no. 08/H0604/69). Pa-
tient characteristics are shown in Suppl. Table-1 and Consort diagram in
Fig. S1. Previously untreated breast cancer patients with either histolog-
ically proven locally advanced breast cancer or tumor N3 cm in diameter
were included. Bevacizumab was administered as single infusion
(15 mg/kg) 2 weeks prior to neoadjuvant chemotherapy.
Multiparametric DCE-MRI scans, core biopsies and blood samples
were obtained immediately before and 2 weeks after bevacizumab. 47
previously untreated locally advanced primary breast cancer patients
were enrolled between July 2008 and November 2010 by the Oxford
Radcliffe Hospital NHS Trust (n = 30) and Mount Vernon Hospital
(n= 17). The present study focuses on ductal cancers (n= 36); analy-
sis of other subtypes will be presented elsewhere. DCE-MRI data was
analysable for 35 patients only.
2.2. Outcomes: DCE-MRI
Treatment response was measured by DCE-MRI. High temporal res-
olution T1-weighted acquisition was used to images 8–12 central slices
of the tumor region. DCE-MRI setup, imaging acquisition details and all
image processing and derivation of PK parameters are reported in detail
in the Suppl. Methods. Furthermore, all scripts and codes used for the
analysis have been submitted to the GitHub public directory: https://
github.com/nph/MRI.Side effects reporting followed CTCAEv3.0
(http://ctep.cancer.gov).
2.3. Molecular Proﬁling
An experienced radiologist obtained the ultrasound guided core bi-
opsies using 14 gauge core biopsy needles with 22 mm throw from
the margin of tumours. Affymetrix Human Exon 1.0 ST arrays were
used to measure gene expression. To conﬁrm gene expression results,
quantitative real-time PCR (qRT-PCR) was performed using same
cDNA as used for gene expression array work. Another ultrasound guid-
ed core biopsy sample was collected directly on biopsy cassettes imme-
diately immersed in 50mLs of 10% Formalin in standard biopsy pot for
immunohistochemistry (IHC) analysis. All samples were processed
within 7 days of collection to render formalin-ﬁxed parafﬁn-embedded
(FFPE) blocks (stored at room temperature). Further details on samples
handling and storage, and analysis methods are in Suppl. Methods.
2.4. Statistical Analysis
Statistical analysis for DCE-MRI, gene expression proﬁling and PCR
are reported in Suppl. Methods. Changes of immunohistochemistry pa-
rameter scores after bevacizumab were analyzed using paired non-parametric method (Wilcoxon Signed Rank Sum, WSRS). Correlation
analyses between gene expression scores, MRI parameters, clinical var-
iables, IHC parameters scores were also performed using non-paramet-
ric methods (Spearman for continuous, Kruskal-Wallis for categorical
variables). GraphPad PRISM v4.0c, Matlab and R v2.13.0 were used.
2.5. Funding
Breast Cancer Research Foundation, Breast Cancer Research Trust,
NIHR Oxford Biomedical Research Centre, and Oxford Cancer Research
UK Imaging Centre. Roche provided bevacizumab free of charge. EU
FP7 p-medicine and Eureca projects supported FMB and RVS.
3. Results
3.1. Highly Heterogeneous Early Response to Bevacizumab
Single-dose bevacizumab administration (15mg/kg) waswell toler-
ated with no grade 3 toxicity in 36 patients (Table S1). Of six patients
presenting erythematous breast mass, four showed reduced erythema
(Fig. S2). No changes after treatment could be detected by standard clin-
ical evaluation (Fig. S2); however DCE-MRI analysis revealed signiﬁcant
decrease in median Ktrans and kep (WSRS, P b 0.001) (Fig. 1a), and
Minkowski–Bouligand fractal dimension (WSRS P = 0.012, Fig. S3).
This suggests general improvement in hierarchical architecture, hence
tendency to vasculature normalisation.
DCE-MRI response was heterogeneous (Fig. 1b, S3), with high base-
line median Ktrans tumours showing greatest reduction (Spearman
ρ=−0.92, P = 1e−08, Fig. 1c). Variability in median Ktrans was also
observed within individual tumours (Fig. 1d). Visual assessment of
parametric maps conﬁrmed this heterogeneity, revealing patterns
from not-signiﬁcant change to strong median Ktrans reduction across
complete tumor mass (Fig. 1d). As different parameter distributions
could result in similar median Ktrans values, we investigated cumulative
Ktrans over the central tumor region. This new parameter, deﬁned here
as total Ktrans, provides an estimate of total target mass presented for
modiﬁcation by bevacizumab, and might help deﬁning heterogeneity
(Fig. 2). Total Ktrans decreased post-bevacizumab (WSRS, P b 0.0001)
(Fig. 2c), changes were correlated with pre-bevacizumab Total Ktrans
(Fig. 2d), and highly variable (Fig. 2e).
3.2. Angiogenesis is Downregulated Whilst VEGFA Transcript is Induced
Gene-wise paired differential expression analysis revealed 23 signif-
icantly (FDR b 0.05) downregulated genes post-bevacizumab (Fig. 3a)
(Table S2). High correlation between gene expression arrays and qRT-
PCR conﬁrmationwas observed (Fig. 3b–c, Figs. S4, S5). Notably, several
(6/23) were also downregulated post-bevacizumab in our xenograft
models (Masiero et al., 2013) including GPR56, inhibitor of VEGF pro-
duction; EXO1, exonuclease promoting cleavage of transcribed immu-
noglobulin switch regions; ILF2, coding for nuclear factor of activated
T-cells (NFAT) component.
Top downregulated transcript was endothelial cell speciﬁc mole-
cule-1 (ESM1), regulated by VEGFA, mediating angiogenesis and inva-
sion. Interestingly, we observed signiﬁcantly greater ESM1
downregulation in high grade tumours (Fig. S5). Other downregulated
genes conﬁrmed by qRT-PCR were fms-related tyrosine kinase 1
(FLT1), encoding a VEGF receptor (VEGFR) family member, and delta
like ligand 4 (DLL4), vascular-speciﬁc Notch ligand (Fig. S4). Signiﬁcant
reduction inmicrovascular areawas also observed.Namely, plasmalem-
ma vascular associated protein (PLVAP) showed an average 20% per-
centage decrease post-treatment (WSRS P = 0.014) (Figs. 4, S6).
A 393 signiﬁcantly upregulated genes were also identiﬁed (Fig. 3a,
Table S3), including VEGFA itself (conﬁrmed by qRT-PCR, Fig. S7) sug-
gesting a negative feedback loop. Interestingly, chemokine receptor
CXCR4, upregulated by VEGFA, and its ligand chemokine stromal cell-
Fig. 1. a) Graph show average median pharmacokinetic parameters. Blue - pre-bevacizumab; red = post-bevacizumab; Bev = bevacizumab; *** = signiﬁcant; ns = not signiﬁcant. b)
Waterfall plot showing absolute change in Median Ktrans after bevacizumab across whole study population. c) Graph show signiﬁcant negative correlation of absolute change in
median Ktrans with pre-bevacizumab median Ktrans. d) Ktrans maps of eleven representative patients showing change in Ktrans after bevacizumab. Arranged in increasing reduction in
Median Ktrans after bevacizumab. Pre-Bev = pre-bevacizumab; Post-Bev = post-bevacizumab; “P”= patient.
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Transcription factor (TF) over-representation analysis (Table S4)
showed activation of ETS2 post-treatment, required for endothelial cell
survival during embryonic angiogenesis, andwhose expression in ﬁbro-
blasts modulates angiogenesis in breast cancer (Wallace et al., 2013).
Similarly for, Lymphoid Enhancer-Binding Factor, LEF1, binding to T-
cell receptor-alpha enhancer and involved inWnt signaling; and for Nu-
clear factor of activated T-cells, NFAT, regulator of signaling between
cancer and stroma cells [as reviewed in (Mancini and Toker, 2009)].
Notably, 59 of these 393 genes were also upregulated post-
bevacizumab in our xenograft models (Table S5); including interleukins
(ILs) such as IL5, IL receptors IL1R1 and IL7R. Interestingly, IPA upstream
regulator analysis (Table S5) found IL12 (P = 1.63E−06), IL4 (P =
7.18E−06), IL13 (P = 1.07E−05), interferon alpha (P = 1.61E−05)
and IL7 (P = 1.18E−05) as most enriched upstream regulators. The
ﬁrst four are inhibitors of angiogenesis; the latter controls proliferation
by inﬂuencing the tumor microenvironment, is over-expressed in triple
negative breast cancers (Lehmann et al., 2011) and has been found to
induce VEGFD and increase lymphangiogenic in preclinical systems
(Al-Rawi et al., 2005) which could highlight potential escape
mechanism.3.3. Decrease in Tumor Proliferation After Bevacizumab
Cyclin E coding gene CCNE1, essential for cell cycle control at G1/S
transition, was also consistently downregulated (Figs. 1, S4). Cyclin E
is associatedwith chromosome instability, is prognostic in breast cancer
(Scaltriti et al., 2011), and lowmolecular weight isoforms increased an-
giogenesis in humanmelanoma cells in-vivo (Bales et al., 2005). Of note,
TF over-representation analysis (Table S4) predicted increased activity
of FOXO4, negative cell cycle regulator and inhibitor of proliferation.
Concordantly, a human breast cancer proliferation signature (Desmedtet al., 2008) (paired t-test P = 0.04, Figs. 4a1 and S8), and percentage
of Ki-67 positive cells decreased (WSR test P = 0.006) (Figs. 4b1 and
S6). Interestingly, reduction was greater in grade 3 than grade 2 cases
(Fig. S9).3.4. Immune Checkpoint Signaling and Metabolism Upregulation After
Bevacizumab
Transcriptional upregulation after bevacizumab was more variable
than downregulation (Fig. 1), suggesting after initial general response
to bevacizumab, distinct adaptation mechanisms are rapidly induced
in patient subgroups. Key immune response pathways were induced
(Tables S3–S5), including CD28 and its activating binding ligand CD86.
Importantly, expression levels of immune checkpoint receptor CTLA4,
inhibitory binding partner of CD86, and negative regulator of T-cell acti-
vation and function, were also increased after treatment (Table S3), as
was IL10 receptor alpha, IL10RA, suppressor of anti-tumor T-cell re-
sponse (Table S3).
Top upregulatedmetabolismgenes, conﬁrmed byqRT-PCR, included
pyruvate dehydrogenase kinase-1 (PDK1) and phosphodiesterase 3B
cGMP-inhibited (PDE3B) (Fig. S7). We analyzedwhether thesemetabo-
lism changes could result from increased tumor hypoxia due to de-
creased blood vessel supply. Several HIF1A target genes were
signiﬁcantly upregulated post-treatment (Fig. S10), similarly to xeno-
graft models (Table S3). These included PHD3 (EGLN3), regulator of
HIF1 degradation; HIF1A regulated ENO2, HK2, PDK1 and VEGFA; and
SPP1 andDDIT4, involved in PI3K-Akt signaling. A human cancer hypox-
ia signature (Buffa et al., 2010) was increased in a patient subgroup
(Figs. 4a2, S8). Furthermore, percentage of CA9 and HIF1A positive
cells were increased (WSRS P = 0.04) (Figs. 4b2, S11). Notably, in 7/
36 patients (20%) both CA9 andHIF1Awere upregulated,whilst no con-
sistent downregulation was observed (Fig. S11).
Fig. 2. a) Change inMedianKtrans after bevacizumab in three representativepatients. b) Change in Total Ktrans after bevacizumab in samepatients; c)Graph showing signiﬁcant reduction in
Total Ktrans after bevacizumab. d) Graph show signiﬁcant negative correlation of absolute change in Total Ktrans with pre-bevacizumab Total Ktrans. e) Waterfall plot showing absolute
change in Total Ktrans after bevacizumab across whole study population.
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Fig. 3. a) Heatmap of differentially expressed genes after bevacizumab. Each row represents a differentially expressed gene arranged by ascending order of fold change from top to bottom
and each column represents fold change for single patients, red= up-regulation and blue= down-regulation, samples were visually clustered using hierarchical clustering. (b) Heatmap
showing high variation in gene expression (as analyzed by exon array) of genes validated by qRT-PCR. Each row represents a gene and each column represents single patient's fold change
for each gene post-bevacizumab. Red= up-regulation, Blue= down-regulation. (c) Signiﬁcant correlation between fold changes in genes of interest as observed by exon array and qRT-
PCR. Yellow boxes represents genes signiﬁcantly changing by exon array as well as qRT-PCR analysis.
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Firstly, we divide patients into responders and non-responders
using a DCE-MRI binary classiﬁcation. Speciﬁcally, only patients show-
ing 30% or greater reduction in median Ktrans were categorised as re-
sponders (Ah-See et al., 2008). This classiﬁcation might seem
conservative, however it considers the variability in DCE-MRI parame-
ter estimation which has been discussed extensively in previous work
(Othman et al., 2016; Beuzit et al., 2016; Wang et al., 2015). In particu-
lar, it deﬁnes as signiﬁcant changes, hence response to treatment, only
those changes in median Ktrans which are above the average level of
noise observed in our (Ah-See et al., 2008) and other group's (Li et al.,
2014) previous breast cancer studies.
To assess this classiﬁcation, we exploited recently published human
cancer angiogenesis (Masiero et al., 2013) and VEGF-blockade (Bais et
al., 2011) signatures. These identiﬁed coherent response groups (Fig.
S12), and a group of 12 patients with consistent downregulation of
DCE-MRI and these signatures. Conversely, a coherent resistance proﬁle
was identiﬁed in 5 patients (Fig. S12). Differential pathway activation
analysis was undertaken (Table S6, Fig. S12) which considers linked ex-
pression of genes within the same pathway, recovering some statistical
power. This revealed decreased activation of the Hippo pathway in re-
sponders; namely, downregulation of STK3 and linked upregulation of
LATS2, an inhibitor angiogenesis (Dai et al., 2013). Furthermore, activa-
tion of axon guidance, including VEGFA-regulated RND1 and PLXNA1,decreased in responders whilst increased in non-responders; and
mTOR signaling and carbohydrate metabolism, including PGM1, in-
creased in non-responders whilst decreased in responders. Although
agreement between DCE-MRI and molecular proﬁling is encouraging,
it is clear that when using such DCE-MRI binary classiﬁcation, the
non-responder group is small (n = 8), hindering statistical power.
Next, we considered Ktrans as continuous response variable and dis-
covered 471 genes whose expression changes post-bevacizumab were
positively correlated with total Ktrans changes (FDR b 0.05), showing
greater downregulation in responder cases (Table S7). Pathways analy-
sis (Table S8) indicated downregulation of Wnt signaling (FDR =
0.002), extracellular matrix (ECM) receptor interaction
(FDR b 0.0001), cell adhesion molecules (FDR = 0.0009), MAPK
(FDR = 0.0105), and VEGF (FDR = 0.0123) signaling. This was con-
ﬁrmed by gene set analysis (GSA) where changes in MAPK, ECM and
NFAT gene sets were positively correlated with change in total Ktrans
(Fig. 5). Furthermore, human cancer angiogenesis and VEGF-blockade
signatures were both downregulated in cases with greatest decrease
in total Ktrans (Spearman rho = 0.40, P = 0.02; and rho = 0.39, P =
0.02 respectively). This conﬁrms greater DCE-MRI response is
characterised by downregulation of angiogenesis and proliferation.
Finally, strong increase in hypoxia and HIF1A regulated genes was
seen in non-responder cases (Fig. S12), and increase in hypoxia marker
CA-9 by IHC was correlated with increased VEGFA protein levels by
ELISA (Spearman r = 0.51, P = 0.002) (Fig. S13). This suggests that
Fig. 4. a)Heatmap showinghigh variability in genes involved in Proliferation, Hypoxia andAngiogenesis signatures. Each row represents a gene and each column represents single patient.
Colors reﬂect the fold change for each gene post-bevacizumab. With whole cohort of study patients (n = 36), signiﬁcant global down-regulation of the proliferation signature (paired t-
test: t=−2.09, P-value= 0.04) but no signiﬁcant change in the speciﬁc breast cancer hypoxia signature (paired t-test: t=−0.20, P-value= 0.84), angiogenesis signature (paired t test:
t=0.81, P-value= 0.42). b) IHC sections showing signiﬁcant downregulation of proliferationmarker (Ki67) (P=0.01), upregulation of carbonic anhydrase-9 (P= 0.04), upregulation of
Hypoxia inducible factor 1 alpha (HIF1a) (P = 0.001) and down-regulation of plasmalemma vascular associated protein (PLVAP) (P = 0.02) in response to bevacizumab.
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than normalized blood vessel network, with consequent increase in
hypoxia.
3.6. Baseline DCE-MRI Predicts Downregulation of Angiogenesis
Initial DCE-MRI Ktrans status was the strongest predictor of response,
namely tumours with high median Ktrans at baseline demonstrated the
greatest decrease in Ktrans post-bevacizumab (Fig. 1c). To exclude re-
gression to mean artefacts, this was conﬁrmed using transcriptional
proﬁles, which showed that tumours with high baseline median Ktrans
respond to bevacizumab with downregulation of angiogenesis, whilst
patients with low initial values of median Ktrans show no or little varia-
tion in angiogenesis. Speciﬁcally, 110 genes showed changes after
bevacizumab thatwere signiﬁcantly negatively correlatedwith baseline
median Ktrans, namely downregulated post-bevacizumab in tumours
with higher baselinemedianKtrans (Table S9). Pathways included angio-
genesis, cell adhesion and NFAT (Table S10).
Similar analysis using total Ktrans identiﬁed 1080 genes whose
changes were negatively correlated with baseline total Ktrans, namely
downregulated post-bevacizumab in patients with high baseline total
Ktrans (Table S11). All but one (TMEM129, an uncharacterized trans-
membrane protein) of 110 negatively correlated genes in median Ktrans
analysis were conﬁrmed in total Ktrans analysis, indicating highagreement between these two parameters but possibly greater power
when using total Ktrans. Similarly, GSA highlighted 11 gene sets whose
post-bevacizumab changes were negatively correlated with baseline
median Ktrans, and 29 with baseline total Ktrans (Fig. 5). Of note, angio-
genesis signatures were top-downregulated sets, followed by wide
spectra of angiogenesis-related pathways.
4. Discussion
Monitoring and early prediction of patient response to therapy is in-
creasingly important, particularly because of heterogeneity of response
to expensive or toxic agents, and missed opportunity of effective thera-
py by early switching. Many drugs, although targeted to highly speciﬁc
processes, are not targeted to genetic lesion, so it is difﬁcult to select pa-
tients on baseline genetic criteria. For anti-angiogenic treatment, this is
even more important as effectiveness is small overall but likely to have
substantial beneﬁt inminority of patients. It is notable that median pro-
gression-free interval in many trials of bevacizumab is often only 4–
6 weeks, and 1–2 weeks overall survival beneﬁt, suggesting this early
pattern is what sets agenda for ﬁnal beneﬁt. Our aimwas to linkmacro-
scopic heterogeneity of response to molecular pathways that are
targetable.
We combined monitoring by DCE-MRI andmolecular proﬁling with
short-term ﬁrst-line treatment in primary breast cancer to measure
Fig. 5. Heatmap of gene set analysis for expression changes post-bevacizumab associated
with DCE-MRI parameters. The DCE-MRI parameters considered were: baseline median
and total Ktrans; and changes (Δ) in median and total Ktrans. Gene Set Analysis (GSA)
algorithm was used (see Methods); the GSA score is shown and colour-bar is provided
with absolute values. This represents the strength of the positive and/or negative
association between the speciﬁc gene set (y-axis) and the speciﬁc DCE-MRI parameter
(x-axis). Gene sets that were signiﬁcant (FDR b 0.05) in at least one of the four analyses
are shown. The sets included were the full GSEA Biocarta gene set V3 (http://www.
broadinstitute.org/gsea/msigdb/collections.jsp), a previously derived hypoxia signature
(Buffa et al., 2010) (not shown in the heatmap as never signiﬁcant), ER and ERBB2
signaling signatures (not shown as never signiﬁcant), proliferation and Wnt signatures
(“Wnt signaling”) (Desmedt et al., 2008), a recently derived angiogenesis signature
(“Angiogenesis”) (Masiero et al., 2013) and VEGF-blockade signature (“Anti-VEGF”)
(Bais et al., 2011).
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imaging we can never sample to the same extent, but only conduct
small number of biopsies. Furthermore, previous work from our (Ah-
See et al., 2008) and other groups (Othman et al., 2016; Beuzit et al.,
2016;Wang et al., 2015) has demonstratedDCE-MRI parameter estima-
tion can depend on a variety of factors including normal physiologicalvariability, MRI set-up and acquisition protocols, and different image
processingmethods. Strikingly, in spite of this, we observed strong cor-
relations of functional imaging with molecular changes, regardless of
the DCE-MRI method used to categorize the patients (binary response,
continuous median Ktrans and total Ktrans), reﬂecting heterogeneity of
response and providing added molecular information.
DCE-MRI showed initial response to bevacizumab in most patients.
Speciﬁcally, 91% (32/35) patients showed decrease in median Ktrans,
and 77% (27/35) had a N30% decrease. This indicates a general initial
vascular normalisation, and downregulation of angiogenic factors
ESM1 and FLT1. Interestingly, another family member, FLT4, was predic-
tive for bevacizumab response in ovarian cancer (Collinson et al., 2013).
Importantly, strong downregulation of proliferation post-
bevacizumab suggests a critical role of even aberrant leaky vessels in
providing enough nutrients and oxygen for growth. This has implication
for current routine practice, and supports combination of anti-angio-
genic treatment with chemotherapy to further inhibit growth as is usu-
ally the case, but with little previous rationale.
Whilst this work was submitted, a study was published (Tolaney et
al., 2015)with similarwindowdesign, but a lower dose of bevacizumab.
Decreased microvessel density [MVD] at 2 weeks was observed. We,
however, reveal the complex response to anti-bevacizumab therapy at
an early timepoint, when this response can be evaluated alone.
Notwithstanding initial response, our study revealed heterogeneity
ranging from tumours developing central necrosis to continuous
growth. In fact, it is clear that a subgroup of patients experienced vessels
normalisation, with decreased proliferation. Equally, there is another
group of patients where HIF1α and regulated genes (e.g. CA9), necrosis
and angiogenesis increase. So we showed that vascular normalisation is
likely to be amechanism of response, but there is a subgroup of patients
where changes are induced in response to hypoxia which can actually
induce further vessel production and resistance, such as induction of
CXCR4 and metabolism. This suggests a feedback loop in these patients
where an initial response potentially shuts down, rather than normal-
ize, blood supply with consequent induction of hypoxia. These resis-
tance mechanisms offer great opportunities for combination therapy
as we have already demonstrated in preclinical models (McIntyre et
al., 2012; Favaro et al., 2012; Li et al., 2007).
Importantly, immune checkpoint genes were induced on treatment,
including CTLA4, and its ligand CD86, which could antagonize CD28 T-
cell activation. Although CTLA4 has greater CD86 afﬁnity than CD28
(Linsley et al., 1991); co-presence of activating/inhibiting signaling sug-
gests co-existence of recruited versus non-recruited T-cell pockets in
these tumours. Recently, ProgrammedDeath Ligand 1, PD-L1, not show-
ing signiﬁcant changes in this study but member of the same CD28/
CTLA4 family of receptors, has been shown to be direct target of
HIF1A, and when blocked under hypoxia it enhanced myeloid-derived
suppressor cells-mediated T-cell activation (Noman et al., 2014). We
cannot ascertain at this stage whether this is to speciﬁc antibody effects
or interaction with hypoxia; however, these ﬁndings support beneﬁt
from combination of bevacizumab with novel immune checkpoint in-
hibitors to restore and boost T-cell immune response.
Finally, we found that macroscopic analysis of whole tumours could
predict response, and baseline Ktrans was the strongest predictor, which
suggests VEGF is main determinant of vascular leakiness, though not
necessarily angiogenesis. Although baseline gene expression did not
strongly correlate with MRI variation, once an environmental stress
was induced there was strong concordance between imaging and
mRNA changes, enabling patient classiﬁcation by gene response linked
to imaging changes with therapy implications. Control theory indicates
difﬁculty of relating response to baselines if rules for connection are un-
known, but our results showhowquickly tumours adapt and then allow
the characteristics to be deﬁned.
We conclude that bevacizumab has been prematurely discontinued,
rather than focusing on ﬁnding subgroups of patients whomost beneﬁt
using monitoring during 2 week window before continuing therapy.
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or other targeted therapies.
Finally, we suggest new paradigms for clinical research. Firstly, trials
should incorporate appropriate initial enrichment of patients with high
Ktrans, and a range of therapeutic options to meet potential early resis-
tance pathways induced. Then, early imaging will be needed to stratify
patients into categories likely to have different mechanism of adapta-
tion, and biopsies to select patients for appropriate combinations. Re-
peatability of these assays makes this widely feasible. Multi-arm
adaptive trials are ongoing usingmolecularmarkers for targeted agents,
but we suggest this needs to be further modiﬁed by much earlier adap-
tation when using drugs affecting the tumor microenvironment.
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